- Synta Pharmaceuticals (SNTA +4.2%) moves higher in early trading.
- The shares are likely getting a lift from news that collaborators at Johns Hopkins and Duke's Dana-Farber Cancer Institute have separately published results which the company says "demonstrate the ability of ganetespib to down-regulate a number of key proteins involved in tumor growth and metastasis." (PR)
Synta Pharmaceuticals jumps on publication of ganetespib results
Nov 22 2013, 09:36 ET